- Title
- Aerosol delivery of palivizumab in a neonatal lamb model of respiratory syncytial virus infection
- Creator
- Edirisinghe, Hasindu; Rajapaksa, Anushi; Royce, Simon; Sourial, Magdy; Bischof, Robert; Anderson, Jeremy; Sarila, Gulcan; Nguyen, Cattram; Mulholland, Kim; Do, Lien; Licciardi, Paul
- Date
- 2023
- Type
- Text; Journal article
- Identifier
- http://researchonline.federation.edu.au/vital/access/HandleResolver/1959.17/198900
- Identifier
- vital:19105
- Identifier
-
https://doi.org/10.3390/v15112276
- Identifier
- ISSN:1999-4915 (ISSN)
- Abstract
- (1) Background: Palivizumab has been an approved preventative monoclonal antibody for respiratory syncytial virus (RSV) infection for over two decades. However, due to its high cost and requirement for multiple intramuscular injections, its use has been limited mostly to high-income countries. Following our previous study showing the successful lung deposition of aerosolised palivizumab in lambs, this current study evaluated the “proof-of-principle” effect of aerosolised palivizumab delivered as a therapeutic to neonatal lambs following RSV infection. (2) Methods: Neonatal lambs were intranasally inoculated with RSV-A2 on day 0 (day 3 post-birth) and treated with aerosolised palivizumab 3 days later (day 3 post-inoculation). Clinical symptoms, RSV viral load and inflammatory response were measured post-inoculation. (3) Results: Aerosolised therapeutic delivery of palivizumab did not reduce RSV viral loads in the nasopharynx nor the bronchoalveolar lavage fluid, but resulted in a modest reduction in inflammatory response at day 6 post-inoculation compared with untreated lambs. (4) Conclusions: This proof-of-principle study shows some evidence of aerosolised palivizumab reducing RSV inflammation, but further studies using optimized protocols are needed in order to validate these findings. © 2023 by the authors.
- Publisher
- Multidisciplinary Digital Publishing Institute (MDPI)
- Relation
- Viruses Vol. 15, no. 11 (2023), p.
- Rights
- All metadata describing materials held in, or linked to, the repository is freely available under a CC0 licence
- Rights
- https://creativecommons.org/licenses/by/4.0/
- Rights
- Copyright © 2023 by the authors
- Rights
- Open Access
- Subject
- 3107 Microbiology; Aerosolisation; Lamb model; Lung; Palivizumab; Respiratory syncytial virus
- Full Text
- Reviewed
- Funder
- This study was supported by the Jack Brockhoff Foundation’s Early Career Research Grant awarded to A.E.R. and the Victorian Government Operational Infrastructure Support Program. A.E.R. was supported by a National Health and Medical Research Council (NHMRC) Early Career Fellowship (GNT1123030) and an NHMRC Development Grant (GNT1139340).
- Hits: 306
- Visitors: 305
- Downloads: 1
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | SOURCE1 | Published version | 4 MB | Adobe Acrobat PDF | View Details Download |